TLDR summary of SUSTAIN trials: Diabetic and overweight patients controlled their diabetes and lost weight when treated with injectable semaglutide, even more so as compared to standard diabetic medication
Semaglutide is a GLP-1 analogue that was initially approved as a once-weekly subcutaneous injection (Ozempic , 0.5, 1.0 and 2.0 mg) for treating T2D [6, 7]
The FDA has received reports of dosing errors associated with compounded GLP-1s, including patients accidentally taking too much or too little and experiencing complications such as fainting, dehydration and severe gastrointestinal symptoms
Chronic Conditions : Certain health conditions, like hypothyroidism or diabetes, can cause persistent tiredness
Dimenticanze In caso di dimenticanza della dose di Ozempic: se sono trascorsi 5 giorni o meno dal giorno previsto iniettarlo non appena ce ne si ricorda, dopodich iniettare la dose successiva nel giorno programmato